Hyloris Reports Full Year 2020 Financial Results (GlobeNewswire) - Mar 9, 2021 - "Maxigesic IV is a novel combination of Paracetamol 1000mg + Ibuprofen 300mg solution for infusion for use post-operatively in hospitals for patients...successful completion of a second Phase 3 study in 232 subjects to support regulatory filing to the FDA. The submission of a scientific paper in a peer reviewed journal is currently being prepared....Maxigesic IV: submission of marketing application to the FDA by AFT Pharmaceuticals...With cash and cash equivalents of €64.40 million at year-end, the Company is well-capitalised to advance all current pipeline assets as planned and execute on its ambitious growth strategy with 14 commercial products expected by 2024."
Clinical • Commercial • Trial completion • CNS Disorders • Pain
|